About

Garry E. Kiefer, Ph.D. is the Director of Research and Development for Macrocyclics. He received a Ph.D. in Organic/Coordination

Chemistry from Louisiana State University in 1984 under the mentorship of Professor George R. Newkome.

In 1985 he accepted a position with the Dow Chemical Company working in Discovery Research focusing on innovative chelation chemistry technologies for diagnostic and therapeutic medicine. During his 20 year career he played a major role in the design and synthesis of numerous chelating agent platforms that were instrumental for Dow’s various medical chelation programs. His major accomplishments include the design of DOTA-based bifunctionals for nuclear medicine applications, leading the development of innovative targeted contrast agent technologies for magnetic resonance and optical imaging, and discovery of the mechanism for targeting lanthanide chelates to cancer cells through structure/activity relationships.

In addition to his technical accomplishments Dr. Kiefer was active in the supervision of external collaborators, and management of intellectual assets and commercial strategies. He was recognized as the Dow Gulf Coast Scientist of the year on two occasions (1993 and 1999) and as the Dow Gulf Coast Inventor of the Year in 1996. In 2005 Dr. Kiefer retired from Dow and assumed his current position with Macrocyclics. Since that time he has focused on expanding the company’s GMP capabilities and new product offerings as well as strategic partnerships. Dr. Kiefer also holds an appointment as Research Professor of Chemistry at the University of Texas at Dallas. His research interests include the architectural design of targeted chelates that can function as physiological probes. Dr. Kiefer has published over 100 peer reviewed articles and 40 patents.